http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고산소에 노출된 신생 백서와 성숙 백서에 있어서Peroxiredoxin I과 II의 발현
이창률,김형중,안철민,김성규 대한결핵및호흡기학회 2002 Tuberculosis and Respiratory Diseases Vol.53 No.1
Expression of Peroxiredoxin I and II in Neonatal andAdult Rat Lung Exposed to Hyperoxia 배 경 :포유동물은 고산소 노출되면 이에 적응하기 위해 성숙 폐장의 항산화 효소의 활성도가 증가하는 것으로 알려져 있다. 신생 폐장에서는 이들의 활성도가 뚜렷이 증가하고 이는 고산소 노출에 내성을 보이는 중요한 기전으로 알려져 있다. Peroxiredoxin은 세포내 항산화 효소로 세포내 많은 양이 존재하고 다양한 세포에 분포하고 있다. 그중 Prx I 및 II는 세포질에 존재하는 주된 동종 효소이다.본 연구는 고산소를 투여하여 성숙 백서의 폐장에서 Prx Ⅰ과 PrxⅡ mRNA 및 단백의 발현을 평가하여 신생 백서의 폐장에서의 발현과 비교하고자 하였다. 방 법 :성숙 백서와 임신 백서로부터 분만하여 얻은 신생 백서를 무작위로 고산소를 시간별로 투여후에 폐조직과 기관지폐포세척액을 얻었다. Prx I 및 Prx II mRNA는 Northernblot 방법으로 구하였으며 Actin mRNA을 내부 기준으로 하여 상대 발현을 평가하였다. Prx I 및 Prx II 단백은 Westernblot 방법으로 구하였으며 Actin 단백을 내부 기준으로
이창률,홍지영,이명구,서인범 연세대학교의과대학 2017 Yonsei medical journal Vol.58 No.6
Purpose: Pleural effusion, an accumulation of fluid in the pleural space, usually occurs in patients when the rate of fluid formation exceeds the rate of fluid removal. The differential diagnosis of tuberculous pleurisy and malignant pleural effusion is a difficult task in high tuberculous prevalence areas. The aim of the present study was to identify novel biomarkers for the diagnosis of pleural fluid using proteomics technology. Materials and Methods: We used samples from five patients with transudative pleural effusions for internal standard, five patientswith tuberculous pleurisy, and the same numbers of patients having malignant effusions were enrolled in the study. We analyzedthe proteins in pleural fluid from patients using a technique that combined two-dimensional liquid-phase electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Results: We identified a total of 10 proteins with statistical significance. Among 10 proteins, trasthyretin, haptoglobin, metastasis-associated protein 1, t-complex protein 1, and fibroblast growth factor-binding protein 1 were related with malignant pleural effusionsand human ceruloplasmin, lysozyme precursor, gelsolin, clusterin C complement lysis inhibitor, and peroxirexdoxin 3 were expressed several times or more in tuberculous pleural effusions. Conclusion: Highly expressed proteins in malignant pleural effusion were associated with carcinogenesis and cell growth, and proteins associated with tuberculous pleural effusion played a role in the response to inflammation and fibrosis. These findings will aid in the development of novel diagnostic tools for tuberculous pleurisy and malignant pleural effusion of lung cancer.
이창률,Jeong Hee Jeon,김형중,Dong Hwan Shin,Tae Woong Roh,안철민,Yoon Soo Chang 대한내과학회 2008 The Korean Journal of Internal Medicine Vol.23 No.3
Background/Aims: The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and its prognostic implications in non-small-cell lung cancer (NSCLC) are still controversial. Methods: Seventy-one paraffin-embedded tissue sections from stage I NSCLC patients were stained using a mouse monoclonal antibody against human IGF-1R. Results: The intensity and frequency of IGF-1R expression on the membrane and cytoplasm of cancer cells was evaluated and scored using a semiquantitative system. IGF-1R expression was detected in nine of 71 (12.7%) cases. No significant relationship was found between clinical/histopathological parameters and IGF-1R expression. None of the patients whose tumor expressed IGF-1R had experienced distant metastasis or cancer-related death, although the difference did not reach statistical significance. Conclusions: We conclude that IGF-1R expression may not be a major prognostic factor for stage I NSCLC.
이창률 대한중환자의학회 2010 Acute and Critical Care Vol.25 No.4
Sepsis is a common illness of intensive care unit patients that carries high morbidity and mortality, and increases hospital costs. Although mortality from sepsis remains high when compared with other critical illnesses, it has declined over the last few decades due to several adjunctive therapies and focused care programs or guidelines. In 2004, an international guideline was published that the bedside clinician could use to improve the outcomes in severe cases of sepsis and septic shock. Several landmark studies recently demonstrated that therapeutic strategies may substantially reduce mortality. The Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock: 2008 was updated using a new evidence-based methodology system for assessing the quality of evidence and the strengths of recommendations. Evidence-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improving the outcomes of critically ill patients. This article discusses the guidelines and current insights into sepsis treatment.